For the treatment of Rheumatoid Arthritis, Diacerein, an anthraquinone derivative, is known for its chondroprotective and anti-inflammatory properties. It has the potential to be therapeutic, however, its clinical value is limited by factors like poor solubility, low bioavailability, and gastrointestinal adverse effects. An extensive summary of cutting-edge delivery strategies created to improve the effectiveness of Diacerein, and patient adherence is given in this review. These delivery techniques include transdermal patches for non-invasive administration, liposomes and nanoparticles for enhanced bioavailability and targeted distribution, topical gels for localized treatment, and oral tablets with modified-release formulations. Furthermore, new technologies promising for regulated and sustained release include hydrogel-based systems microneedles, etc. The assessment also looks at the field's possibility from now on, highlighting the necessity of using improved biomaterials including carriers of medications in personalized medical techniques. Future research attempts to maximize the therapeutic profile of Diacerein, better Rheumatoid Arthritis management, and improve patient outcomes by resolving present issues and utilizing cutting-edge technologies. Realizing these objectives will depend heavily on existing clinical studies and technological developments. This review aims to better understand Diacerein's conventional formulations and comprehend their future improvement.

For the treatment of Rheumatoid Arthritis, Diacerein, an anthraquinone derivative, is known for its chondroprotective and anti-inflammatory properties. It has the potential to be therapeutic, however, its clinical value is limited by factors like poor solubility, low bioavailability, and gastrointestinal adverse effects. An extensive summary of cutting-edge delivery strategies created to improve the effectiveness of Diacerein, and patient adherence is given in this review. These delivery techniques include transdermal patches for non-invasive administration, liposomes and nanoparticles for enhanced bioavailability and targeted distribution, topical gels for localized treatment, and oral tablets with modified-release formulations. Furthermore, new technologies promising for regulated and sustained release include hydrogel-based systems microneedles, etc. The assessment also looks at the field's possibility from now on, highlighting the necessity of using improved biomaterials including carriers of medications in personalized medical techniques. Future research attempts to maximize the therapeutic profile of Diacerein, better Rheumatoid Arthritis management, and improve patient outcomes by resolving present issues and utilizing cutting-edge technologies. Realizing these objectives will depend heavily on existing clinical studies and technological developments. This review aims to better understand Diacerein's conventional formulations and comprehend their future improvement.